References
- Müller T, Arbeiter K, Aufricht C. Renal function in meningomyelocele: risk factors, chronic renal failure, renal replacement therapy and transplantation. Curr Opin Urol. 2002;12:479–484.10.1097/00042307-200211000-00006
- Reitz A, Schurch B. Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord. 2004;42:267–272.10.1038/sj.sc.3101584
- Bauer SB, Austin PF, Rawashdeh YF, et al. International children’s continence society’s recommendations for initial diagnostic evaluation and follow-up in congenital neuropathic bladder and bowel dysfunction in children. Neurourol Urodyn. 2012;31:610–614.10.1002/nau.v31.5
- The Tethered Spinal Cord: Diagnosis by High-Resolution Real-Time Ultrasound [Internet]. PubMed Journals. Available from: https://ncbi.nlm.nih.gov/labs/articles/6611916/
- Glasier CM, Chadduck WM, Leithiser RE, et al. Screening spinal ultrasound in newborns with neural tube defects. J Ultrasound Med. 1990;9:339–343.10.7863/jum.1990.9.6.339
- Jeruto A, Poenaru D, Bransford R. Clean intermittent catheterization: overview of results in 194 patients with spina bifida. Afr J Paediatr Surg. 2004;1:20.
- Sinha MD, Gibson P, Kane T, et al. Accuracy of ultrasonic detection of renal scarring in different centres using DMSA as the gold standard. Nephrol Dial Transplant. 2007;22:2213–2216.10.1093/ndt/gfm155
- Campbell JB, Moore KN, Voaklander DC, et al. Complications associated with clean intermittent catheterization in children with spina bifida. J Urol. 2004;171:2420–2422.10.1097/01.ju.0000125200.13430.8a
- Dias MS. Neurosurgical management of myelomeningocele (spina bifida). Pediatr Rev. 2005;26:50–60.10.1542/pir.26-2-50
- Kennelly MJ. A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010;12:12–19.
- Verpoorten C, Buyse GM. The neurogenic bladder: medical treatment. Pediatr Nephrol Berl Ger. 2008;23:717–725.10.1007/s00467-007-0691-z
- Donnellan CA, Fook L, McDonald P, et al. Oxybutynin and cognitive dysfunction. BMJ. 1997;315:1363–1364.10.1136/bmj.315.7119.1363
- Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol. 1998;160:892–896.
- Wan J, Rickman C. The durability of intravesical oxybutynin solutions over time. J Urol. 2007;178:1768–1770.10.1016/j.juro.2007.03.181
- Botox. FDA prescribing information, side effects and uses [Internet]. Drugs.com. Available from: https://www.drugs.com/pro/botox.html
- Lazarus J. The paediatric neuropathic bladder. S Afr Med J. 2014. Available from: https://www.samj.org.za/index.php/samj/article/view/8046
- Husmann DA. Malignancy after gastrointestinal augmentation in childhood. Ther Adv Urol. 2009;1:5–11.10.1177/1756287209104163